These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 24369793)

  • 1. Relationship between serum galectin-3 values and demographical or biochemical variables in patients without acute coronary syndrome.
    Lippi G; Salvagno GL; Bonfanti L; Cervellin G
    Int J Cardiol; 2014 Feb; 171(2):270-1. PubMed ID: 24369793
    [No Abstract]   [Full Text] [Related]  

  • 2. Preamble: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for utilization of biomarkers in acute coronary syndromes and heart failure.
    Christenson RH
    Clin Biochem; 2008 Mar; 41(4-5):208-9. PubMed ID: 17765213
    [No Abstract]   [Full Text] [Related]  

  • 3. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
    Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
    Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical experience using galectin-3 in heart failure.
    McCullough PA
    Clin Chem Lab Med; 2014 Oct; 52(10):1425-31. PubMed ID: 24810562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safe diagnosis in acute phase with T-proBNP. Heart failure and acute coronary syndrome can be identified very early].
    Javadzadeh J; Collén AC; Manhem K; Swedberg K
    Lakartidningen; 2008 Feb 27-Mar 4; 105(9):616-9. PubMed ID: 18376704
    [No Abstract]   [Full Text] [Related]  

  • 6. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure.
    Christenson RH; Duh SH; Wu AH; Smith A; Abel G; deFilippi CR; Wang S; Adourian A; Adiletto C; Gardiner P
    Clin Biochem; 2010 May; 43(7-8):683-90. PubMed ID: 20153309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.
    Meijers WC; van der Velde AR; de Boer RA
    Expert Rev Mol Diagn; 2014 Apr; 14(3):257-66. PubMed ID: 24606321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease.
    Tuñón J; Blanco-Colio L; Cristóbal C; Tarín N; Higueras J; Huelmos A; Alonso J; Egido J; Asensio D; Lorenzo Ó; Mahíllo-Fernández I; Rodríguez-Artalejo F; Farré J; Martín-Ventura JL; López-Bescós L
    Am J Cardiol; 2014 Feb; 113(3):434-40. PubMed ID: 24295549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 in heart failure: high levels are associated with all-cause mortality.
    Ueland T; Aukrust P; Broch K; Aakhus S; Skårdal R; Muntendam P; Gullestad L
    Int J Cardiol; 2011 Aug; 150(3):361-4. PubMed ID: 21641051
    [No Abstract]   [Full Text] [Related]  

  • 10. [Natriuretic peptides and their use in clinical practice according to the guidelines of the European Society of Cardiology].
    Stryjewski PJ; Nessler B; Paweł M; Badacz L; Nowak J; Nessler J
    Przegl Lek; 2014; 71(1):33-5. PubMed ID: 24712266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
    Gullestad L; Ueland T; Kjekshus J; Nymo SH; Hulthe J; Muntendam P; McMurray JJ; Wikstrand J; Aukrust P
    Am Heart J; 2012 Dec; 164(6):878-83. PubMed ID: 23194488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial galectin-3 for the monitoring of optimally treated stable chronic heart failure: A pilot study.
    Piper SE; de Courcey J; Sherwood RA; Amin-Youssef GF; McDonagh TA
    Int J Cardiol; 2016 Mar; 207():279-81. PubMed ID: 26808993
    [No Abstract]   [Full Text] [Related]  

  • 14. A pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva.
    Zhang X; Wan Y; Chata R; Brazzale A; Atherton JJ; Kostner K; Dimeski G; Punyadeera C
    J Clin Pathol; 2016 Dec; 69(12):1100-1104. PubMed ID: 27340130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-hospital peak glycemia in non-diabetic patients with heart failure complicating acute coronary syndrome.
    Lazzeri C; Valente S; Chiostri M; D'Alfonso MG; Fatucchi S; Mecarocci V; Gensini GF
    Int J Cardiol; 2014 Sep; 176(1):260-2. PubMed ID: 25037688
    [No Abstract]   [Full Text] [Related]  

  • 16. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
    Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
    Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of galectin-3 in patients with heart failure.
    Bošnjak I; Selthofer-Relatić K; Včev A
    Dis Markers; 2015; 2015():690205. PubMed ID: 25960597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between red blood cell distribution width (RDW) and all-cause mortality at two years in an unselected population referred for coronary angiography.
    Cavusoglu E; Chopra V; Gupta A; Battala VR; Poludasu S; Eng C; Marmur JD
    Int J Cardiol; 2010 May; 141(2):141-6. PubMed ID: 19144426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Red blood cell distribution width and its relation to cardiac function and biomarkers in a prospective hospital cohort referred for echocardiography.
    Holmström A; Sigurjonsdottir R; Hammarsten O; Gustafsson D; Petzold M; Fu ML
    Eur J Intern Med; 2012 Oct; 23(7):604-9. PubMed ID: 22939804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Red cell distribution width as predictive marker in CHF: testing of model performance by reclassification methods.
    Jenei ZM; Förhécz Z; Gombos T; Pozsonyi Z; Jánoskuti L; Prohászka Z
    Int J Cardiol; 2014 Jul; 174(3):783-5. PubMed ID: 24768398
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.